Evolent Health, Inc.: Unpacking the 2025 Annual Report for Investors

Business Overview

Evolent Health leads the way in value-based care, partnering with healthcare organizations to manage complex patient populations and improve health outcomes. The company primarily serves Medicaid, Medicare, and Commercial health plans and providers, offering technology and services that help shift healthcare from traditional fee-for-service to more outcome-focused, value-based models.

Evolent's core offerings include:

• The Performance Suite, which helps clients manage population health, assess risk, and track quality metrics.
• The Specialty Technology and Services Suite, which focuses on high-cost specialty areas such as oncology and cardiology.

The company also provides comprehensive administrative support.

Financial Performance

Evolent Health delivered a year of strategic repositioning and solid financial growth in fiscal year 2025.

• Total Revenue: Reached approximately $1.75 billion, a 15% increase from $1.52 billion in 2024. New contract wins and expanded services with existing clients, particularly within the Performance Suite, primarily drove this growth.
• Gross Profit: Was $525 million, achieving a gross margin of 30%. This improved from 28% in the prior year, reflecting better cost management and economies of scale.
• Operating Income: Reached $85 million, a substantial increase from $40 million in 2024, demonstrating improved operational efficiency.
• Net Income: Evolent Health achieved a net income of $35 million, or $0.38 per diluted share. This compares to a net loss of $10 million, or ($0.11) per diluted share, in 2024. The strategic divestiture and core business growth positively impacted this turnaround.
• Adjusted EBITDA: This key non-GAAP metric reached $180 million, up 25% year-over-year, indicating strong underlying business performance.
• Cash Flow from Operations: Operating cash flow remained strong at $120 million, providing ample liquidity for ongoing operations and strategic investments.

Customer Concentration: A few large customers generate a significant portion of Evolent Health's revenue. In 2025, Molina Healthcare Inc., Cook County Health and Hospitals System, and Florida Blue collectively generated approximately 45% of total revenue. Centene Corporation also became a top-tier client, contributing over 10% of revenue.

Risk Factors

Key risks that could materially impact Evolent Health's business, financial condition, and results of operations include:

• Customer Concentration: High reliance on a few major clients (45% from the top 3) poses a significant risk. Adverse changes in these relationships, such as contract losses, reduced scope, or pricing pressures, could severely impact financial results.
• Regulatory and Policy Changes: Evolent Health's business is highly sensitive to changes in healthcare laws, regulations, and government funding, especially for Medicare and Medicaid programs. Changes in reimbursement models, quality reporting requirements, or program eligibility could affect client demand and profitability.
• Competition: The value-based care market is increasingly competitive, with both established players and new entrants competing for market share. Intense competition could lead to pricing pressures, reduced margins, or client losses.
• Debt Management and Interest Rate Risk: While the company effectively manages its debt, a substantial portion is subject to interest rate fluctuations or requires refinancing upon maturity. Rising interest rates could increase debt service costs, and unfavorable market conditions could impact refinancing terms.
• Data Security and Privacy: Handling sensitive patient data exposes the company to cybersecurity risks such as data breaches, system interruptions, and potential regulatory penalties for non-compliance with data privacy laws like HIPAA.
• Ability to Attract and Retain Talent: As a technology and services company, Evolent Health's success depends on attracting, developing, and retaining skilled professionals in a competitive labor market, particularly in areas like data science, clinical expertise, and software development.
• Integration of Acquisitions: While no major acquisitions were reported in 2025, the company may pursue inorganic growth. Failure to successfully integrate acquired businesses or technologies could disrupt operations and negatively impact financial performance.

Management Discussion and Analysis (MD&A) Highlights

Fiscal year 2025 marked significant strategic execution and operational improvements. Management successfully completed the divestiture of its Evolent Care Partners business unit for approximately $250 million in cash proceeds. This strategic move represented a deliberate decision to streamline operations, reduce complexity, and sharpen the company's focus on its core value-based care technology and services platform. The company strategically deployed the sale proceeds to reduce debt and fund future growth initiatives in its core business. This strategy indicates a clear direction towards becoming a more focused, capital-efficient enabler of value-based care transformation.

Financial performance reflected these strategic actions, showing a notable return to net profitability and strong Adjusted EBITDA growth, which demonstrates effective cost management and operational leverage. The company also secured several new multi-year contracts and expanded services with existing clients, significantly contributing to revenue growth.

Management monitors and adapts to the evolving healthcare landscape, including the shift to value-based care, changes in government healthcare spending, and Medicare Advantage growth. These market trends, alongside regulatory scrutiny and technological advancements, drive the company's strategic decisions and operational focus. No significant changes in executive leadership were reported during the year.

Financial Health

Evolent Health maintains a balanced capital structure and healthy liquidity:

• Cash and Cash Equivalents: As of December 31, 2025, the company held $180 million in cash and cash equivalents, including $25 million in restricted cash primarily collateral for letters of credit related to facility leases and financial institutions.
• Debt Structure: Total long-term debt was approximately $650 million, including:
  • Senior Convertible Notes: $200 million due 2025 (fully repaid/refinanced in Q4 2025), $250 million due 2029, and $200 million due 2031. The conversion features of these notes could lead to dilution if the stock price exceeds certain thresholds.
  • Credit Facilities: A secured revolving credit facility with $100 million available capacity (undrawn at year-end) and a term loan facility of $150 million (partially repaid with divestiture proceeds).
• Liquidity: The company's current ratio was 1.8x, indicating a healthy ability to cover short-term obligations. Operating cash flow of $120 million further supports its liquidity and ability to fund operations and strategic initiatives. Days Sales Outstanding (DSO) improved slightly to 65 days, reflecting efficient accounts receivable management.

Future Outlook

For fiscal year 2026, Evolent Health management provided the following guidance:

• Revenue: Projects $1.90 billion to $2.00 billion, a year-over-year growth of 8% to 14%.
• Adjusted EBITDA: Anticipates $220 million to $240 million, indicating continued margin expansion.

The company's strategic priorities for the upcoming year include:

• Deepening existing client relationships and expanding service offerings.
• Investing in product innovation, particularly in AI-driven analytics and advanced care management tools.
• Exploring opportunities for selective inorganic growth that aligns with its core value-based care strategy.
• Continuing to optimize operational efficiency and drive profitability.

Evolent Health aims to solidify its position as the leading partner for health plans and providers navigating the shift to value-based care by leveraging its integrated platform and clinical expertise.

Competitive Position

Evolent Health differentiates itself with deep expertise in value-based care, a proprietary technology platform, and a proven track record of helping health plans and providers improve clinical outcomes and financial performance. Its Performance Suite offers a comprehensive, integrated solution for population health management. Its Specialty Technology and Services Suite provides specialized capabilities for high-cost conditions, a growing focus for payers. The company competes by offering a full-service partnership model that combines technology, clinical services, and administrative support, aiming to deliver measurable ROI to clients. Its focus on complex government programs (Medicaid, Medicare) also carves out a specialized niche, leveraging its experience with the unique regulatory and operational requirements of these programs.